Stay Updated
For all press requests, please reach out to [email protected].
News and Reports
ICYMI: Big Pharma Sinks to the Bottom of U.S. Industry Rankings
KEY POINTS: “The pharmaceutical industry is now the most poorly regarded industry in Americans’ eyes, ranking last on a list of 25 industries that Gallup tests annually.” “The new low in the pharmaceutical industry’s U.S. image comes amid a range of criticisms of industry norms, from generating the highest drug costs in the world to […]
News and Reports
Pharma: A Broken Market Begging for Repairs
Washington Examiner // David Mitchell // Aug. 20, 2019 KEY POINT: “Government policy keeps U.S. drug prices high, and only government reforms can change that.” I am a cancer patient, and I’m losing patience. Despite lots of promises, pronouncements, and plans from both political parties, more than half way into 2019 we have not lowered […]
Press Releases
10 Drug Corporations Drive One-Third of Taxpayer Spending in Medicare Part D
WASHINGTON, DC — Negotiating for the 250 most-expensive drugs in Medicare Part D would address nearly 80 percent of all spending in the program, according to an updated analysis by Patients For Affordable Drugs. The analysis, using data from CMS’ Medicare Part D Drug Spending Dashboard, found the top 250 drugs cost the program $118 Billion, […]
Press Releases
Vertex is pricing life-saving medicines out of reach.
To: Vertex Pharmaceuticals CEO Jeffrey Leiden We are members of cystic fibrosis, investment, and religious communities, and we agree that Vertex Pharmaceuticals, a Boston-based drug corporation, has priced life-saving drugs out of reach. It’s unfair. It’s unjust. And it must change. Cystic fibrosis is a rare genetic disease that impacts 70,000 to 100,000 people worldwide. […]
Press Releases
CHART PACK: New Analysis Shows Lion’s Share Of Part D Spending is For a Small Percentage of Drugs
WASHINGTON, DC — As Congress moves toward consideration of legislation to enable direct Medicare drug price negotiation, Patients For Affordable Drugs conducted an analysis to determine where the greatest savings could be achieved. The analysis, using data from CMS’ Medicare Part D Drug Spending Dashboard, shows that less than 1 percent of drugs accounts for […]
Press Releases
FIRDAPSE FLOP: BIO Ignores Calls to Disavow Catalyst Pharmaceuticals
WASHINGTON, DC — One of Big Pharma’s major trade organizations has ignored a call from patients to expel Catalyst Pharmaceuticals — the drug maker responsible for increasing the price of an old drug from $0 to $375,000 overnight. Patients For Affordable Drugs sent a letter and a petition with nearly 2,000 signatures last week to Jim […]
Press Releases
STATEMENT: The Price of Insulin is Still Too High
WASHINGTON, DC — In response to today’s news that Eli Lilly will begin selling an authorized generic of Humalog for $137.35 per vial, Ben Wakana, Executive Director of Patients For Affordable Drugs, issued the following statement: “Clearly, the insulin cartel is feeling pressure after years of price gouging a lifesaving drug. But charging nearly $140 […]
News and Reports
ICYMI: Medicare spent $2 billion for one drug as the manufacturer paid doctors millions
KEY POINT Medicare spent nearly $2 billion on H.P. Acthar Gel from 2011-2016, according to the agency’s data — even though some doctors say an equally effective treatment would have cost a tiny fraction of that amount. (CNN)—More than 80% of doctors who filed Medicare claims in 2016 for H.P. Acthar Gel — a drug […]